Research, money and the fight against disease: this is the power of the antibody

By Eppendorf

In 2014, global sales for monoclonal antibodies (mAbs) and mAb-derived products reached $75 billion dollars, which according to US BioProcess Technology Consultants, comprised more than half of the total biopharmaceutical market. It’s not just about the money, as Eppendorf has shown the value of mAbs in treating disease and carrying out diagnostics and research.

Enter your details below to view the free white paper

By downloading this White Paper, you acknowledge that may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Business Trade Media International Limited may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.